The Chamber of Commerce urged a federal judge on Friday to stop the new Medicare drug price negotiation program before Oct. 1 ...
The Southern District Court of Ohio on Friday heard oral arguments from the federal government and the Chamber of Commerce in ...
All of the companies had drugs that made the list of the first 10 medications to be subject to Medicare price negotiations. PhRMA, a leading drug industry trade group, and the US Chamber of ...
“Congress knew that withdrawing all products from federal healthcare programs would be economic suicide—not a ‘real option.’” – U.S. Chamber motion for preliminary injunction On August ...
Aug 31 (Reuters) - Drugmakers challenging a Biden administration program requiring them to negotiate with Medicare over the prices of selected costly drugs may not have a clear legal precedent on ...
One year after IRA passage, bad actors try to thwart drug price negotiation, and Biden’s efforts to defend it fall short. Merck is suing the federal government over a plan to negotiate Medicare drug ...
The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking a swipe at the powerful pharmaceutical industry. It marks a major ...
Japanese drugmaker Astellas (OTCPK:ALPMF) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly ...
Analysis-Drugmakers Could Find Sympathetic US Supreme Court in Drug Pricing Lawsuits By Brendan Pierson (Reuters) - Drugmakers challenging a Biden administration program requiring them to ...
President Joe Biden speaks during an event at the White House promoting lower health care costs on Aug. 29. The administration announced a list of the first 10 drugs subject to Medicare price ...
A major turning point in the battle to control ever-rising drug prices The Biden administration has picked the first 10 high-priced prescription drugs subject to federal price negotiations, taking ...
Aug 31 (Reuters) - Drugmakers challenging a Biden administration program requiring them to negotiate with Medicare over the prices of selected costly drugs may not have a clear legal precedent on ...
